Novartis reports new analysis showing Xolair® improving quality of life by 78% for chronic spontaneous urticaria patients

  • New analysis from pivotal Phase III studies show Xolair® (omalizumab) significantly improved quality of life scores for Chronic Spontaneous Urticaria (CSU) patients compared to placebo[1],[2] 
  • Additional data at WCD show the consistent negative health impact and economic burden of CSU, including anxiety, depression, impact on work ability and health system costs[3],[4] 
  • CSU is a severe skin condition with symptoms such as persistent itching, swelling and a rash that spontaneously presents and re-occurs for more than six weeks[5]-[7]

Basel, 12 June 2015 - Novartis announced today new analyses from pivotal Phase III registration studies showing Xolair® (omalizumab) helps patients with Chronic Spontaneous Urticaria (CSU) achieve significant improvements in quality of life measures. These findings were presented at the 23rd World Congress of Dermatology (WCD) in Vancouver, Canada.

  • The Dermatology Life Quality Index (DLQI), which gives a total score from 0-30, from best to worst QoL, whereby a score of >11 signifies that CSU/CIU has a very large to extremely large effect on a patient`s life.
  • The Chronic Urticaria Quality of Life questionnaire (CU-Q2oL), which measures urticaria-specific QoL (total score from 0-100, from best to worst QoL).
  • Xolair: DLQI - 73-78%; CU-Q2oL - 66-69%.
  • Placebo: DLQI - 22-47%; CU-Q2oL - 32-42%.

 

Suggested Articles

Amid Amgen's pricing war with Sanofi and Regeneron's Praluent, PCSK9 cholesterol fighter Repatha has shown a clinical benefit for HIV patients.

A month after the FDA approved it, Esperion's Nexletol showed it can lower cholesterol regardless of statin and ezitimibe treatment.

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.